美國商業資訊

2025-03-31 19:44

GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan

GE HealthCare has completed its acquisition of Sumitomo Chemical’s 50% stake in Nihon Medi-Physics (NMP), giving it full ownership.
As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease
Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics segment, will also become President of NMP.

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease.

Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become President of NMP, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country. Japan is on a path to becoming a leader in the $7 billion molecular imaging global market1 and a center of excellence for Asian markets. As part of GE HealthCare, NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring next-generation radiopharmaceuticals to the Japan market and beyond.”

NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. GE HealthCare acquired Amersham plc in 2004, and subsequently held a 50% stake in NMP.

The Company expects this transaction to be neutral to Adjusted EPS2 in year one and accretive thereafter.

GE HealthCare was advised by Solomon Partners Securities, LLC.

The intent to acquire the remaining 50% stake in NMP was announced in December 2024.

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the expected results of the transaction, future market conditions, and the Company’s performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; and the Company may assume unexpected risks and liabilities. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedInXFacebookInstagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

1 GE HealthCare estimated global end markets as of December 2023, and estimated market CAGR 2024–2028.
2 Non-GAAP financial measure. See our earnings release dated February 13, 2025 for the definition of Adjusted EPS.

 

Contacts

Media contact
David Morris
Executive, Communications, Pharmaceutical Diagnostics
GE HealthCare
+44 7920591370
david.j.morris@gehealthcare.com

Nihon Medi-Physics headquarters and radiopharmaceutical imaging agents about to go through labelling and packing process.

送禮活動浪接浪!想緊貼著數活動消息?即Like etnet Facebook專頁!► 立即讚好

人氣文章
最近7天
1
收息攻略 | 港元定存無「息」可圖,五招高息替代方案逆勢突圍
2
高息定存 | 一周高息合集,拆息走低銀行逆市升存息搶資金,港元定存5厘以上仲有咩選擇?
3
金油 | 毛偉廉:金油價格因戰急升,回調風險浮現
4
港股 | 蕭猷華:恒指維持大漲小回格局
5
美股 | 特朗普稱對伊朗「失去耐性」,道指跌近300點
6
美股收盤 | 道指微升35點,聯儲局官員稱或最早於7月減息
7
新股攻略 | 四新股搶灘海天三花「孖盡」認購?海天首日料升兩成
8
聯儲議息 | FOCUS | 鮑公再拒「減息令」,侵侵「伊朗牌」拆招?
9
神州經脈 | 人行推八大政策,科創板設成長層,滬港金融協同發展
10
神州經脈 | 消費增速年半高,工業增加值、失業率半年低,股匯漲
1
OCBC宏富理財發佈品牌大使鍾嘉欣 端午聯乘「鴨靈號」閃耀維港 慶祝「新加坡—香港雙樞紐」策略的成功
2
高息定存 | 招商永隆上調一年期港元定存息,滙豐3個月跌穿1厘
3
關稅戰 | 特朗普轉軚,歐盟50%關稅期限暫緩至7月9日
4
星展基金會:以創新推動大灣區樂齡經濟
5
高息定存 | 一周高息合集,三大發鈔行再減存息,工銀亞洲3個月最高5厘
6
高息定存 | 一周高息合集,滙豐兌換外幣資金可享7日10厘,建行亞洲3個月最高5.58厘
7
美股收盤 | 關稅戰再添變數,三大指數各有升跌
8
關稅戰 | 特朗普建議6月1日起對歐盟商品徵50%關稅,斥歐盟貿易壁壘嚴重
9
無人機 | FOCUS | 無人機出奇制勝,新博弈中國藏王牌
10
小米 | 季績勝預期獲大行升目標,股價逆市上升應如何部署?
11
神州經脈 | 比亞迪反擊「汽車圈恒大」質疑,日本水產將恢復進口
12
比亞迪等多家車企承諾帳期60天,專家:應規範支付方式,禁匯票
13
關稅戰 | 美國上訴法院暫緩執行貿易法庭關稅判決,至下月9日
14
高息定存 | 南商1個月美元定期存款年息高達5厘
15
高息定存 | 一周高息合集,個別銀行逆市加息,恒生一周定存息高達10厘
16
關稅戰 | 特朗普據悉施壓要求歐盟單方面降低關稅
17
美股收盤 | 非農就業數據勝預期,標指重上6000點關口
18
關稅戰 | 白宮稱特朗普於周二簽署行政命令,上調鋼鋁稅至50%
19
關稅戰 | 美國財政部罕有瞄準日本央行,要求繼續推動日圓升值
20
港股 | 蕭猷華:恒指本周料先低後高
21
高息定存 | PAObank推港元定存優惠,一個月定存16厘息
22
高息定存 | 富邦上調12個月港元定存年息至2.3厘
23
拆息急跌定存薄利,好息之徒買內銀?高息ETF也可吼?
24
港股 | 蕭猷華:趁港股調整,宜逢低吸納
25
車企血戰 | FOCUS | 車企「口水仗」橫飛,行業陷集體焦慮
26
【後市觀點】恒生證券投資論壇落幕 專家分享2025下半年"危與機"
27
關稅戰 | 5月中國對美國出口大跌34.4%,逾五年最大降幅
28
中東 | 德黑蘭與耶路撒冷密集爆炸,伊朗稱擊落兩架F-35
29
中美元首通話,習近平促共同把握大局,習特邀請互訪
30
收息攻略 | 港元定存無「息」可圖,五招高息替代方案逆勢突圍
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet榮獲HKEX Awards 2024 「最佳證券數據供應商」大獎

etnet榮膺「第九屆傳媒轉型大獎」四大獎項

【限時優惠$68/月】申請etnet強化版MQ手機串流報價服務 捕捉板塊輪動,提高獲利勝算

貨幣攻略

大國博弈

關稅戰

說說心理話

Watch Trends 2025

北上食買玩

Wonder in Art

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老